주사 치료 시장 보고서 : 유형, 약제 클래스별, 투여 경로, 유통 채널, 최종사용자 및 지역별(2026-2034년)

The global rosacea treatment market size reached USD 2.2 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.07% during 2026-2034. The rising demand for oral treatments and the expanding pharmaceutical industry are primarily driving the market.

ROSACEA TREATMENT MARKET ANALYSIS:

• Major Market Drivers: The increasing prevalence of this skin disease due to excessive temperature changes, exercise, the rising application of cosmetics, and the widespread consumption of spicy meals, hot drinks, and alcohol is one of the key factors driving the market growth.
• Key Market Trends: The introduction of artificial intelligence (AI)-powered diagnostic tools that utilize digital image shots in natural white light and resolutions to identify facial lesions and recognize areas prone to rosacea is creating a positive outlook for the market. Moreover, the increasing initiatives and investments by several governments to promote research and development (R&D) activities are anticipated to drive the market in the coming years.
• Competitive Landscape: Some of the prominent market companies include Colorescience, Inc., Croda International Plc, Galderma Laboratories, L.P, Journey Medical Corporation, LEO Pharma Inc., Lupin Limited, Maruho Co., Ltd., Mayne Pharma Commercial LLC, PruGen Pharmaceuticals, and Sol-Gel Technologies Ltd., among many others.
• Geographical Trends: North America currently dominates the global market. Rosacea is a common chronic skin condition that affects a significant portion of the population in the region. The increasing awareness and diagnosis of the condition, especially among adults over 30, is contributing to the growing demand for treatment options.
• Challenges and Opportunities: Lack of awareness regarding symptoms among patients and high treatment costs are hampering the market's growth. However, the rise of telemedicine is making dermatological consultations more accessible, allowing patients to seek advice and diagnosis from specialists even in remote areas. This, in turn, offers market opportunities for earlier diagnosis and treatment, thereby improving patient outcomes.

ROSACEA TREATMENT MARKET TRENDS:

Expanding Older Population

The global ageing population is also a major factor in the market's growth. For instance, according to the World Health Organization (WHO), by 2030, one in every six persons in the world will be 60 or older. Moreover, by 2050, the global population of persons aged 60 and up will double, approximately 2.1 billion. Also, according to an article published by the National Library of Medicine, older adults experience more severe rosacea and have more sensitive and delicate skin than younger patients.

Rising Incidence of Rosacea

The growing prevalence of this skin condition across various regions is a key driver for the market. For instance, according to an article published by Frontiers, rosacea is a chronic inflammatory skin disease with an estimated global prevalence of 5.5%. Additionally, rosacea is common in China, with up to 3.48% of the population affected. It is becoming more recognized as a chronic condition, with patients seeking long-term management solutions. This increase in the number of diagnosed cases is propelling the rosacea treatment market share.

Product Innovations

Pharmaceutical companies are continuously developing new, more effective treatments for rosacea, targeting different aspects of the condition, such as inflammation, vascular issues, and microbial factors. For instance, in May 2024, Dr Reddy's Laboratories introduced doxycycline capsules, 40 mg, in the United States. The product is a tetracycline-class medicine for the treatment of inflammatory lesions associated with rosacea in adults.

GLOBAL ROSACEA TREATMENT INDUSTRY SEGMENTATION:

Breakup by Type:

• Erythematotelangiectatic Rosacea
• Papulopustular Rosacea
• Ocular Rosacea
• Phymatous Rosacea

According to the rosacea treatment market outlook, ETR is characterized by persistent facial redness (erythema) and visible, small, dilated blood vessels (telangiectasias). The primary symptoms include flushing, redness, and sensitivity of the skin, often with a burning or stinging sensation. People with this subtype may also experience dry or rough skin. While papulopustular rosacea resembles acne, with the appearance of red bumps (papules) and pus-filled lesions (pustules) on the skin. It involves recurrent outbreaks of bumps and pimples, often on the central face. These may be accompanied by underlying redness and inflammation. Besides this, ocular rosacea affects the eyes, leading to irritation and inflammation in and around the eyes. Symptoms can include redness, dryness, itching, burning, a gritty feeling, and sensitivity to light. It may cause the eyelids to become inflamed (blepharitis) and can lead to more serious eye problems if left untreated.

Breakup by Drug Class:

• Antibiotics
• Alpha Agonists
• Retinoids
• Corticosteroids
• Immunosuppressants
• Antihypertensive Agents
• Others

Antibiotics currently account for the majority of the total market share

According to the rosacea treatment market forecast report, while antibiotics like doxycycline and tetracycline are often used in rosacea, their primary benefit is not antibacterial but anti-inflammatory. These drugs aid in reducing inflammation in the skin, addressing key symptoms like redness, swelling, and the formation of papules and pustules. Moreover, antibiotics are particularly effective in managing papulopustular rosacea, which involves acne-like breakouts. They help reduce the severity of these flare-ups and prevent new lesions from forming.

Breakup by Route of Administration:

• Topical
• Oral

Currently, topical exhibits clear dominance in the market

According to the rosacea treatment market outlook report, topical treatments are a key part of managing rosacea, especially for those with milder forms of the condition or who prefer to avoid oral medications like antibiotics. These treatments are applied directly to the skin and help control symptoms, such as redness, inflammation, and pustules. Moreover, many patients prefer topical treatments over oral medications like antibiotics due to concerns about side effects, long-term use, and systemic absorption.

Breakup by Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

According to the rosacea treatment market analysis report, hospital pharmacies often serve patients with more severe or complicated forms of rosacea, such as those requiring combination therapy or cases with ocular involvement that need close medical supervision. In contrast, many patients with rosacea prefer the privacy and convenience of ordering treatments online, especially for conditions like rosacea that involve cosmetic concerns. Moreover, retail pharmacies are the most accessible point for many patients looking for OTC rosacea treatments. Many people with mild to moderate rosacea first seek treatments at retail pharmacies.

Breakup by End User:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Hospitals typically treat more severe or complicated cases of rosacea. Patients may be referred to dermatologists for advanced treatment options, or they may present with conditions that require specialized care beyond typical outpatient services. Moreover, homecare for rosacea typically involves long-term management of the condition, focusing on maintaining control of symptoms and preventing flare-ups. This is ideal for patients with milder forms of the condition or those who have already received a diagnosis and a treatment plan from a healthcare provider. Furthermore, specialty clinics focus on personalized care, with treatments tailored specifically for rosacea, often integrating both medical and cosmetic options. These clinics are usually outpatient and handle mild to severe cases, depending on the services provided. This, in turn, is escalating the rosacea treatment market demand across the segmentation.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.

According to the rosacea treatment market statistics, North America exhibited a clear dominance in the market, owing to the prevalence of rosacea, affecting millions of people. For instance, according to an article published by the American Academy of Dermatology Association, rosacea is a common skin disease that affects about 16 million individuals in the United States. Factors, such as increasing urbanization, stress, exposure to pollution, and genetic predispositions are contributing to the condition's growing incidence. This has led to a higher demand for effective treatments. Moreover, awareness campaigns by dermatology associations and pharmaceutical companies also play a role in highlighting treatment options and encouraging patients to seek medical intervention earlier.

COMPETITIVE LANDSCAPE:

The rosacea market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Colorescience, Inc.
• Croda International Plc
• Galderma Laboratories, L.P
• Journey Medical Corporation
• LEO Pharma Inc.
• Lupin Limited
• Maruho Co., Ltd.
• Mayne Pharma Commercial LLC
• PruGen Pharmaceuticals
• Sol-Gel Technologies Ltd.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Rosacea Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Erythematotelangiectatic Rosacea
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Papulopustular Rosacea
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Ocular Rosacea
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Phymatous Rosacea
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Drug Class

• 7.1 Antibiotics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Alpha Agonists
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Retinoids
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Corticosteroids
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Immunosuppressants
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Antihypertensive Agents
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Others
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by Route of Administration

• 8.1 Topical
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Oral
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

• 9.1 Hospital Pharmacy
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Online Pharmacy
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Retail Pharmacy
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Homecare
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Specialty Clinics
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Others
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Colorescience, Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
  • 16.3.2 Croda International Plc
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 Galderma Laboratories, L.P
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Journey Medical Corporation
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 LEO Pharma Inc.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 SWOT Analysis
  • 16.3.6 Lupin Limited
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 Maruho Co., Ltd.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 SWOT Analysis
  • 16.3.8 Mayne Pharma Commercial LLC
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 PruGen Pharmaceuticals
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
  • 16.3.10 Sol-Gel Technologies Ltd.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials